Claudine Prowse

Claudine Prowse

Plus aucun poste en cours

Health Technology
Finance
Consumer Services

Profil

Claudine Prowse worked as an Executive Director of Corporate Development at Ionis Pharmaceuticals, a Research Analyst at CIBC World Markets Corp., a Vice President of Investor Relations at Human Genome Sciences, a Vice President of Investor Relations and Planning at Biogen, a Vice President of Strategy and Investor Relations at Inotek Pharmaceuticals Corp., a Research Analyst at Oppenheimer & Co., a Senior VP of Communications and Investor Relations at Kite Pharma, and a Vice President and Product Manager at Leerink Swann & Co. and MEDACorp, Inc. She also worked as a Senior VP of Strategy and Corporate Development at Rocket Pharmaceuticals, Inc. She received an undergraduate degree from the University of California San Diego and a graduate degree from UC San Diego School of Medicine.

Anciens postes connus de Claudine Prowse

SociétésPosteFin
ROCKET PHARMACEUTICALS, INC. Investor Relations Contact 01/08/2021
Analyst-Equity 31/01/2008
Analyst-Equity 13/01/2008
MEDACorp, Inc. Corporate Officer/Principal -
Leerink Swann & Co. Corporate Officer/Principal -
Voir l'expérience en détail de Claudine Prowse

Formation de Claudine Prowse

University of California San Diego Undergraduate Degree
UC San Diego School of Medicine Graduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Claudine Prowse

Relations

86

Relations au 1er degré

12

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées3
BIOGEN INC.

Health Technology

IONIS PHARMACEUTICALS, INC.

Health Technology

ROCKET PHARMACEUTICALS, INC.

Health Technology

Entreprise privées7

Finance

Finance

Health Technology

Health Technology

Health Technology

Leerink Swann & Co.

Finance

MEDACorp, Inc.

Commercial Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Claudine Prowse
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT